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Abstract
Background: While prolongation of QRS duration and QTc interval during acute myocardial infarc-
tion (AMI) has been reported in animals, limited data is available for these readily available electrocar-
diography (ECG) markers in humans. 
Methods: Diagnostic and prognostic value of QRS duration and QTc interval in patients with sus-
pected AMI in a prospective diagnostic multicentre study were prospectively assessed. Digital 12-lead 
ECGs were recorded at presentation. QRS duration and QTc interval were automatically calculated in 
a blinded fashion. Final diagnosis was adjudicated by two independent cardiologists. The prognostic 
endpoint was all-cause mortality during 24 months of follow-up.
Results: Among 4042 patients, AMI was the final diagnosis in 19% of patients. Median QRS dura-
tion and median QTc interval were significantly greater in patients with AMI compared to those with 
other final diagnoses (98 ms [IQR 88–108] vs. 94 ms [IQR 86–102] and 436 ms [IQR 414–462] vs. 
425 ms [IQR 407–445], p < 0.001 for both comparisons). The diagnostic value of both ECG signatures 
however was only modest (AUC 0.56 and 0.60). Cumulative mortality rates after 2 years were 15.9% 
vs. 5.6% in patients with a QRS > 120 ms compared to a QRS duration ≤ 120 ms (p < 0.001), and 
11.4% vs. 4.3% in patients with a QTc > 440 ms compared to a QRS duration ≤ 440 ms (p < 0.001). 
After adjustment for age and important ECG and clinical parameters, the QTc interval but not QRS 
duration remained an independent predictor of mortality. 
Conclusions: Prolongation of QRS duration > 120 ms and QTc interval > 440 ms predict morta lity 
in patients with suspected AMI, but do not add diagnostic value. (Cardiol J 2018; 25, 5: 601–610)
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Introduction
Acute myocardial infarction (AMI) is a major 
cause of death and disability worldwide. As highly 
effective treatments are available, early and ac-
curate detection of AMI is crucial [1–3]. Clinical 
assessment, the 12-lead electrocardiogram (ECG) 
and cardiac troponin (cTn) form the cornerstones 
for the early diagnosis of AMI [1]. 
The 12-lead ECG recording devices have been 
equipped with software more than two decades ago 
to automatically calculate both QRS duration and 
corrected QT interval (QTc). Animal studies inves-
tigating ECG changes after induction of an ischemic 
state found an acute prolongation of ventricular 
depolarization as reflected by QRS duration and 
of ventricular repolarization as indicated by QTc 
interval, with some suggesting a dose dependent 
effect between the amount of ischemia and the 
prolongation observed [4–6]. In humans, the in-
duction of ischemia during exercise stress testing 
or balloon angioplasty resulted in prolongation of 
both QRS duration and QTc interval [7, 8]. QTc 
prolongation seemed to occur even earlier than 
conventional ECG markers of ischemia including 
ST deviation [8]. Despite this promising experi-
mental data, the diagnostic value of QRS duration 
and QTc interval for the diagnosis of AMI has never 
been assessed in unselected patients presenting 
with symptoms suggestive of AMI.
Besides the need to rapidly rule-in or rule-out 
AMI, risk stratification is important in patients 
presenting with chest pain. Prolongation of QRS 
duration and QTc interval have been identified as 
markers of all-cause and cardiovascular mortality 
in the setting of AMI in the era of thrombolysis 
[9–11]. After the emergence of percutaneous 
coronary interventions as the preferred treatment 
of AMI, both markers were still found to predict 
mortality after AMI independently [12–14]. Due 
to the definitions of AMI applied in these studies, 
most patients suffered from extensive infarctions 
[9–14]. With the introduction of more sensitive 
biomarkers, much smaller AMI’s can be diagnosed 
nowadays [1, 15, 16]. Whether the prognostic value 
of the QRS duration and the QTc interval found 
earlier is still valid for contemporary AMI patients 
diagnosed with high-sensitive cardiac troponin (hs-
cTn) assays is unknown. 
This study therefore assessed the diagnostic 
and prognostic value of QRS duration and QTc 
interval in a large prospective cohort of patients 
presenting to the emergency department (ED) 
with symptoms suggestive of AMI and diagnoses 
adjudicated based on hs-cTn levels. 
Methods
Study design and population
Advantageous Predictors of Acute Coronary 
Syndrome Evaluation (APACE) is an ongoing pro-
spective international multicenter study designed 
to advance the early diagnosis of AMI (ClinicalTri-
als.gov registry, number NCT00470587) [17–20].
Unselected patients presenting to the ED with 
symptoms suggestive of AMI (such as acute chest 
discomfort and angina pectoris) with an onset or 
peak within the last 12 h and an age > 18 years 
were recruited. 
The study was carried out according to the 
principles of the Declaration of Helsinki and ap-
proved by the local ethics committees. Writ-
ten informed consent was obtained from all pa-
tients. The authors designed the study, gathered, 
and analysed the data according to the STARD 
guidelines for studies of diagnostic accuracy (see 
Supplemental Appendix for details), vouch for 
the data and analysis, wrote the paper, and decided 
to publish [21]. 
Routine clinical assessment  
and hs-cTnT measurement
All patients underwent a clinical assessment 
that included medical history, physical examination, 
12-lead ECG, pulse oximetry and standard blood 
test. Levels of high-sensitive cardiac troponin T 
(hs-cTnT, Roche Diagnostics) were measured at 
presentation and serially thereafter as long as 
clinically indicated. For hs-cTnT, limit of blank 
and limit of detection have been determined to be 
3 ng/L and 5 ng/L, an imprecision corresponding to 
10% coefficient of variation was reported at 13 ng/L 
and the 99th-percentile of a healthy reference 
population at 14 ng/L [22]. Timing and treatment 
of patients was left to the discretion of the attend-
ing physician. 
Adjudication of final diagnoses
Two independent cardiologists reviewed all 
available medical records — patient history, physi-
cal examination, results of laboratory testing, 
radiologic testing, ECG, echocardiography, cardiac 
exercise stress test, lesion severity and morphol-
ogy in coronary angiography — pertaining to pa-
tients from the time of ED presentation to 90-days 
follow up. In situations of disagreement about the 
diagnosis, cases were reviewed and adjudicated in 
conjunction with a third cardiologist. Adjudication 
of the final diagnosis was performed centrally in 
a core lab (University Hospital Basel) and included 
two sets of serial cTn measurements: serial cTn 
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measurements obtained as part of routine clinical 
care locally (different (h)s-cTn assays), and serial 
measurements of hs-cTnT from study blood draws 
performed centrally in a core laboratory in order to 
take advantage of the higher sensitivity and higher 
overall diagnostic accuracy offered by hs-cTnT.
Acute myocardial infarction was defined and 
hs-cTn levels interpreted as recommended in cur-
rent guidelines [1]. In brief, AMI was diagnosed 
when there was evidence of myocardial necrosis 
with a significant rise and/or fall in a clinical set-
ting consistent with myocardial ischemia. Details 
on the adjudication of AMI are given in the online 
Supplemental Appendix. 
ECG recording, manual analysis and  
calculation of QRS duration and QTc interval 
At presentation to the ED, a standard 10-s 12-
-lead resting ECG was recorded using a standard 
ECG device at each of the participating institutions 
(including Schiller AG, Baar, Switzerland; Philips- 
Healthcare, Andover, MA, USA; and Customed, 
Ottobrunn, Germany). The patients were instructed 
not to talk during the 10 s, but were allowed to 
breath. The ECG’s were recorded using a sampling 
rate of 500 Hz and a diagnostic signal bandwidth of 
0.05 Hz to 150 Hz in all devices. Before measuring 
the QRS and QT durations, the recorded signals 
were further filtered with a digital 50 Hz AC filter 
(fulfilling the requirements by current international 
ECG device standards). In case of noise on the ECG 
recording, the attending physician on site decided 
whether the degree of noise was acceptable for 
clinical decision making or whether the ECG had 
to be repeated.
All 12-lead resting ECG’s were manually inter-
preted in the ECG core-lab at the University Hos-
pital Basel by internal-medicine specialists blinded 
to clinical and biochemical patient’s details. ECG 
changes indicative of AMI being ST-elevations, 
ST-depressions and T-wave inversions were de-
fined as recommended in current guidelines [1]. 
QRS duration and QT interval were measured 
automatically using standard ECG software. The 
QRS duration was measured from the beginning 
of the first detected Q-wave from all 12 averaged 
QRS complexes, to the end of the last S-wave from 
all 12 averaged QRS complexes. The QT interval 
was measured from the beginning of the first QRS 
taken from all 12 averaged leads to the end of the 
last T-wave taken from all 12 averaged leads. The 
QT interval was adjusted for mean heart rate to 
calculate the QTc interval using the Bazett formula 
[23]. Prolonged QRS interval was prospectively 
defined as QRS interval > 120 ms [24], and pro-
longed QTc interval was prospectively defined as 
QTc interval > 440 ms [25].
The digital ECG archive of the University Hos-
pital Basel was further interrogated with regards 
to previous ECG’s recorded within 90 days before 
the index admission. If available, those ECG’s were 
used to calculate the difference in QRS duration 
and QTc interval.
Follow-up 
After hospital discharge, patients were con-
tacted after 3, 12 and 24 months by telephone or 
in written form. Information regarding death was 
furthermore obtained from the national registry on 
mortality, the hospital’s diagnosis registry and the 
family physician records.
Statistical analysis
Continuous variables are presented as mean 
(standard deviation) or median (interquartile range 
[IQR]); categorical variables as numbers and per-
centages. Differences in baseline characteristics 
were assessed using the Mann-Whitney U test for 
continuous variables and the Pearson c2 test for 
categorical variables. Receiver-operating-charac-
teristic (ROC) curves were constructed to assess 
the diagnostic accuracy for the diagnosis of AMI 
for the QRS duration and QTc interval. Survival 
during 2 years of follow-up according to QRS dura-
tion and QTc interval was plotted in Kaplan-Meier 
curves, and the log-rank test was used to assess 
differences in mortality between groups. Univariate 
Cox proportional hazard analysis to compute hazard 
ratios (HR) and 95% confidence intervals (CI) for 
the dichotomized QRS duration and QTc interval as 
well as for other electrocardiographic (conventional 
ECG changes indicative of AMI, left bundle branch 
block) and clinical (age, sex, creatinine clearance, 
hs-cTnT, diagnosis of AMI, history of AMI or coro-
nary artery disease [CAD]) predictors of death were 
used. A multivariable model was then built including 
all significant predictors from univariate analysis.
All hypothesis testing was two-tailed and 
p-values < 0.05 were considered statistically sig-
nificant. All statistical analyses were performed 
using IBM SPSS for Windows 23.0 (IBM SPSS 
Inc, Chicago, IL). 
Results
Enrolment and characteristics of patients
From April 2006 to August 2015, a total of 
4323 unselected patients were enrolled. Patients 
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with unknown diagnosis after adjudication and at 
least one elevated hs-cTnT level possibly indicat-
ing AMI were excluded (n = 99), as were patients 
with missing ECG at presentation (n = 90) or 
ECGs with ventricular pacing (n = 92). This left 
4042 patients eligible for analysis (Fig. 1). Baseline 
characteristics of the 4042 patients with acute 
chest pain are shown in Table 1. The adjudicated 
final diagnosis was AMI in 764 (19%) patients. 
Unstable angina was the diagnosis in 377 (9%), 
cardiac symptoms of origin other than CAD in 552 
(14%), non-cardiac symptoms in 2185 (54%) and 
symptoms of unknown origin in 164 (4%).
Levels of QRS duration and QTc interval
QRS duration of more than 120 ms was recorded 
in 9% of patients, QTc interval of more than 440 ms 
in 32% of patients, respectively. Baseline char-
acteristics of those groups are shown in Tables 1 
and 2. Patients with prolonged QRS duration or 
QTc interval were older, had more cardiovascular 
comorbidities and were more often taking cardiac 
medication. 
Diagnostic value of QRS duration  
and QTc interval for the diagnosis of AMI
Overall, the median QRS duration was 94 ms 
(IQR 86–104). Median QRS-duration was sig-
nificantly longer in patients with AMI compared 
to those with other causes of chest pain (98 ms 
[IQR 88–108] vs. 94 ms [IQR 86–102], p < 0.001), 
however with a large overlap. Accordingly, the di-
agnostic accuracy of QRS duration at presentation 
for diagnosis of AMI as quantified by the area under 
the ROC curve (AUC) was only modest with 0.56 
(95% CI 0.54–0.59). 
The median QTc interval overall was 426 ms 
(IQR 409–448). Median QTc interval was sig-
nificantly longer in patients with AMI compared to 
those with other causes of chest pain (436 ms [IQR 
414–462] vs. 425 ms [IQR 407–445], p < 0.001). 
Accordingly, the diagnostic accuracy of QTc interval 
at presentation for the diagnosis of AMI as quanti-
fied by the AUC was again only modest with 0.60 
(95% CI 0.58–0.62).
In a subset of 361 patients, a previous ECG 
within the last 90 days was available for comparison 
and to assess the value of changes in QRS dura-
tion or QTc interval. Between AMI and non-AMI 
patients, a difference was neither found in the 
change of QRS duration (median change 0 ms [IQR 
–5 – 8] vs. 2 ms [IQR –4 – 6], p = 0.68), nor in the 
change of the QTc interval (median change 6.5 ms 
[IQR –18 – 27] vs –4 ms [IQR –20 – 13], p = 0.08). 
Prognostic value of the QRS duration  
for the prediction of mortality during  
long-term follow-up
During a median follow-up duration of 25 
months in survivors, 285 (7%) patients died. 
Median QRS duration was significantly higher 
in patients dying compared to survivors (102 ms 
[IQR 90–119] vs. 94 ms [IQR 86–102], p < 0.001). 
Cumulative mortality rates after 2 years were 
15.9% and 5.6% in patients with a QRS > 120 ms 
compared to patients with a QRS duration ≤ 120 ms 
(p < 0.001, Fig. 2A). This was observed in both 
patients with AMI and in patients with other dia-
gnoses (p < 0.001 for both comparisons, Fig. 2B, C). 
These findings were also unchanged if patients 
with ST-segment elevation myocardial infarction 
(STEMI) were excluded and only patients with 
non-ST-segment elevation myocardial infarction 
(NSTEMI) were analyzed (data not shown). 
In univariate Cox proportional hazard analy-
sis, a QRS duration > 120 ms predicted mortality 
with a HR of 2.95 (95% CI 2.23–3.90, p < 0.001). 
After adjusting for important clinical and electro-
cardiographic parameters, the QRS duration was 
no longer significant (Table 3). 
Prognostic value of the QTc interval  
for the prediction of mortality during  
long-term follow-up
Median QTc interval was significantly higher in 
patients dying compared to survivors (450 ms [IQR 
Figure 1. Patient flow diagram; AMI — acute myocardial 
infarction; ECG — electrocardiogram; hs-cTnT — high-
-sensitive cardiac troponin T.
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425–476] vs. 426 ms [IQR 408–446], p < 0.001). 
Cumulative mortality rates after 2 years were 
11.4% and 4.3% in patients with a QTc > 440 ms 
compared to patients with a QTc interval ≤ 440 ms 
(p < 0.001, Fig. 3A). This was observed in both 
patients with AMI and in patients with other diag-
noses (p < 0.001 for both comparisons, Fig. 3B, C). 
These findings were also unchanged if patients 
with STEMI were excluded and only patients with 
NSTEMI’s were analyzed (data not shown).
In univariate Cox proportional hazard analysis, 
a QTc interval > 440 ms predicted mortality with 
a HR of 2.94 (95% CI 2.32–3.71, p < 0.001). After 
multivariable adjustment as described above, the 
QTc interval remained an independent predictor of 
mortality (HR 1.40, 95% CI 1.07–1.83, p = 0.01; 
Table 3). 
Discussion
This study assessed the diagnostic and prog-
nostic value of QRS duration and QTc interval in 
a large prospective international multicenter cohort 
of 4141 patients presenting with symptoms 
Table 1. Baseline characteristics of the patients.
All patients  
(n = 4042)
AMI  
(n = 764)
Non–AMI  
(n = 3278)
P
Age [years] 61 (49–74) 70 (58–80) 59 (47–72) < 0.001
Female gender 1309 (32%) 202 (26%) 1107 (34%) < 0.001
History:
Arterial hypertension 2450 (61%) 576 (75%) 1874 (57%) < 0.001
Diabetes 677 (17%) 196 (26%) 481 (15%) < 0.001
Coronary artery disease 1301 (32%) 316 (41%) 985 (30%) < 0.001
Previous myocardial infarction 918 (23%) 244 (32%) 674 (21%) < 0.001
COPD 408 (10%) 75 (9.8%) 333 (10%) 0.78
Peripheral occlusive artery disease 217 (5%) 82 (11%) 135 (4%) < 0.001
Chronic kidney disease 352 (9%) 130 (17%) 222 (7%) < 0.001
Medication:
Acetylsalicylic acid 1431 (35%) 344 (45%) 1087 (33%) < 0.001
Thienopyridines 438 (11%) 95 (12%) 343 (11%) 0.12
Oral anticoagulation 359 (9%) 69 (9.0%) 290 (9%) 0.87
Beta-blocker 1347 (33%) 299 (39%) 1048 (32%) < 0.001
Ca-antagonists 583 (14%) 129 (17%) 454 (14%) 0.03
Amiodarone 71 (2%) 13 (2%) 58 (2%) 0.90
Diuretics 936 (23%) 266 (35%) 670 (20%) < 0.001
ACE-inhibitors 848 (21%) 205 (27%) 643 (20%) < 0.001
AT2-blockers 707 (18%) 159 (21%) 548 (17%) 0.007
Statins 1379 (34%) 303 (40%) 1076 (33%) < 0.001
Laboratory:
Hs-cTnT at presentation [ng/L] 8 (4–20) 63 (28–179) 7 (4–12) < 0.001
Creatinine clearance [mL/min/1.73 m2] 85 (70–101) 76 (59–97) 87 (72–102) < 0.001
ECG findings:
QRS duration [ms] 94 (86–104) 98 (88–108) 94 (86–102) < 0.001
QTc interval [ms] 426 (409–448) 436 (414–462) 425 (407–445) < 0.001
ST-segment elevation 193 (5%) 125 (16%) 68 (2%) < 0.001
ST-segment depression 407 (10%) 237 (31%) 170 (5%) < 0.001
T-wave inversion 520 (13%) 202 (26%) 318 (10%) < 0.001
No signs of ischemia 3171 (79%) 370 (49%) 2801 (86%) < 0.001 
Numbers are presented as median (IQR) or numbers (%). ACE — angiotensin converting enzyme; AMI — acute myocardial infarction;  
AT2 — angiotensin 2; COPD — chronic obstructive pulmonary disease; ECG — electrocardiogram; Hs-cTnT — high-sensitive cardiac troponin T
606 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 5
T
ab
le
 2
. B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
o
f t
he
 p
at
ie
nt
s 
ac
co
rd
in
g 
to
 Q
R
S
 d
ur
at
io
n 
an
d
 Q
T
c 
in
te
rv
al
.
A
ll 
p
at
ie
nt
s 
 
(n
 =
 4
04
2)
Q
R
S
 >
 1
20
 m
s 
 
(n
 =
 3
51
)
Q
R
S
 ≤
 1
20
 m
s 
 
(n
 =
 3
69
1)
P
Q
T
c 
>
 4
40
 m
s 
 
(n
 =
 1
31
0)
Q
T
c 
≤ 
44
0 
m
s 
 
(n
 =
 2
73
2)
P
A
ge
 [y
ea
rs
]
61
 (4
9–
74
)
76
 (6
4–
82
)
60
 (4
8–
73
)
<
 0
.0
01
68
 (5
7–
79
)
57
 (4
6–
70
)
<
 0
.0
01
Fe
m
al
e 
ge
nd
er
13
09
 (3
2%
)
94
 (2
7%
)
12
15
 (3
3%
)
0.
02
55
3 
(4
2%
)
75
6 
(2
8%
)
<
 0
.0
01
H
is
to
ry
:
A
rt
er
ia
l h
yp
er
te
ns
io
n
24
50
 (6
1%
)
29
7 
(8
5%
)
21
53
 (5
8%
)
<
 0
.0
01
96
4 
(7
4%
)
14
86
 (5
5%
)
<
 0
.0
01
D
ia
b
et
es
67
7 
(1
7%
)
80
 (2
3%
)
59
7 
(1
6%
)
0.
00
2
28
5 
(2
2%
)
39
2 
(1
4%
)
<
 0
.0
01
C
o
ro
na
ry
 a
rt
er
y 
d
is
ea
se
13
01
 (3
2%
)
18
9 
(5
4%
)
11
12
 (3
0%
)
<
 0
.0
01
48
5 
(3
7%
)
81
6 
(3
0%
)
<
 0
.0
01
P
re
vi
o
us
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n
91
8 
(2
3%
)
12
9 
(3
7%
)
78
9 
(2
1%
)
<
 0
.0
01
32
6 
(2
5%
)
59
2 
(2
2%
)
0.
02
C
O
P
D
40
8 
(1
0%
)
57
 (1
6%
)
35
1 
(1
0%
)
<
 0
.0
01
16
5 
(1
3%
)
24
3 
(9
%
)
<
 0
.0
01
P
er
ip
he
ra
l o
cc
lu
si
ve
 a
rt
er
y 
d
is
ea
se
21
7 
(5
%
)
40
 (1
1%
)
17
7 
(5
%
)
<
 0
.0
01
10
6 
(8
%
)
11
1 
(4
%
)
<
 0
.0
01
C
hr
o
ni
c 
ki
d
ne
y 
d
is
ea
se
35
2 
(9
%
)
82
 (2
3%
)
27
0 
(7
%
)
<
 0
.0
01
18
5 
(1
4%
)
16
7 
(6
%
)
<
 0
.0
01
M
ed
ic
at
io
n:
A
ce
ty
ls
al
ic
yl
ic
 a
ci
d
 
14
31
 (3
5%
)
17
9 
(5
1%
)
12
52
 (3
4%
)
<
 0
.0
01
52
7 
(4
0%
)
90
4 
(3
3%
)
<
 0
.0
01
T
hi
en
o
p
yr
id
in
es
43
8 
(1
1%
)
58
 (1
7%
)
38
0 
(1
0%
)
<
 0
.0
01
15
5 
(1
2%
)
28
3 
(1
0%
)
0.
21
O
ra
l a
nt
ic
o
ag
ul
at
io
n
35
9 
(9
%
)
67
 (1
9%
)
29
2 
(8
%
)
<
 0
.0
01
19
0 
(1
5%
)
16
9 
(6
%
)
<
 0
.0
01
B
et
a-
b
lo
ck
er
13
47
 (3
3%
)
18
1 
(5
2%
)
11
66
 (3
2%
)
<
 0
.0
01
52
4 
(4
0%
)
82
3 
(3
0%
)
<
 0
.0
01
C
a-
an
ta
go
ni
st
s
58
3 
(1
4%
)
79
 (2
3%
)
50
4 
(1
4%
)
<
 0
.0
01
25
1 
(1
9%
)
33
2 
(1
2%
)
<
 0
.0
01
A
m
io
d
ar
o
ne
71
 (2
%
)
16
 (5
%
)
55
 (2
%
)
<
 0
.0
01
52
 (4
%
)
19
 (1
%
)
<
 0
.0
01
D
iu
re
tic
s
93
6 
(2
3%
)
16
9 
(4
8%
)
76
7 
(2
1%
)
<
 0
.0
01
45
5 
(3
5%
)
48
1 
(1
8%
)
<
 0
.0
01
A
C
E
-in
hi
b
ito
rs
84
8 
(2
1%
)
12
2 
(3
5%
)
72
6 
(2
0%
)
<
 0
.0
01
34
2 
(2
6%
)
50
6 
(1
9%
)
<
 0
.0
01
A
T
2-
b
lo
ck
er
s
70
7 
(1
8%
)
99
 (2
8%
)
60
8 
(1
7%
)
<
 0
.0
01
28
5 
(2
2%
)
42
2 
(1
5%
)
<
 0
.0
01
S
ta
tin
s
13
79
 (3
4%
)
18
8 
(5
4%
)
11
91
 (3
2%
)
<
 0
.0
01
51
0 
(3
9%
)
86
9 
(3
2%
)
<
 0
.0
01
La
b
o
ra
to
ry
:
H
s-
T
nT
 a
t p
re
se
nt
at
io
n 
[n
g/
L]
8 
(4
–2
0)
20
 (9
–4
7)
8 
(4
–1
8)
<
 0
.0
01
13
 (6
–3
6)
7 
(4
–1
4)
<
 0
.0
01
C
re
at
in
in
e 
cl
ea
ra
nc
e 
[m
L/
m
in
/1
.7
3 
m
2 ]
85
 (7
0–
10
1)
71
 (5
4–
90
)
86
 (7
1–
10
2)
<
 0
.0
01
79
 (6
2–
97
)
88
 (7
3–
10
3)
0.
00
4
E
C
G
 fi
nd
in
gs
:
Q
R
S
 d
ur
at
io
n 
[m
s]
94
 (8
6–
10
4)
14
0 
(1
30
–1
52
)
93
 (8
6–
10
0)
<
 0
.0
01
98
 (8
8–
11
4)
94
 (8
6–
10
0)
<
 0
.0
01
Q
T
c 
in
te
rv
al
 [m
s]
42
6 
(4
09
–4
48
)
46
7 
(4
42
–4
94
)
42
4 
(4
07
–4
44
)
<
 0
.0
01
45
9 
(4
48
–4
75
)
41
5 
(4
01
–4
27
)
<
 0
.0
01
S
T
-e
le
va
tio
n
19
3 
(5
%
)
1 
(0
.3
%
)
19
2 
(5
%
)
<
 0
.0
01
57
 (4
%
)
13
6 
(5
%
)
0.
39
S
T
-d
ep
re
ss
io
n
40
7 
(1
0%
)
10
 (3
%
)
39
7 
(1
1%
)
<
 0
.0
01
18
7 
(1
4%
)
22
0 
(8
%
)
<
 0
.0
01
T
-w
av
e 
in
ve
rs
io
n
52
0 
(1
3%
)
55
 (1
6%
)
46
5 
(1
3%
)
0.
10
24
3 
(1
9%
)
27
7 
(1
0%
)
<
 0
.0
01
N
o
 s
ig
ns
 o
f i
sc
he
m
ia
31
71
 (7
9%
)
28
9 
(8
2%
)
28
82
 (7
8%
)
0.
07
93
0 
(7
1%
)
22
41
 (8
2%
)
<
 0
.0
01
 
N
um
b
er
s 
ar
e 
p
re
se
nt
ed
 a
s 
m
ed
ia
n 
(IQ
R
) o
r 
nu
m
b
er
s 
(%
). 
A
C
E
 —
 a
ng
io
te
ns
in
 c
o
nv
er
tin
g 
en
zy
m
e;
 A
T
2 
—
 a
ng
io
te
ns
in
 2
; 
C
O
P
D
 —
 c
hr
o
ni
c 
o
b
st
ru
ct
iv
e 
p
ul
m
o
na
ry
 d
is
ea
se
; 
E
C
G
 —
 e
le
ct
ro
ca
rd
io
gr
am
; 
 
H
s-
cT
nT
 —
 h
ig
h-
se
ns
iti
ve
 c
ar
d
ia
c 
tr
o
p
o
ni
n 
T
www.cardiologyjournal.org 607
Janosch Cupa et al., Diagnostic and prognostic value of QRS duration and QTc interval in patients with chest pain
Figure 2. Kaplan-Meier curves for the cumulative sur-
vival according to QRS duration. Kaplan-Meier curves 
displaying survival during 2 years of follow-up accord-
ing to QRS duration in (A) the overall group of patients 
with chest pain, (B) the subgroup of patients with acute 
myocardial infarction, and (C) those with other causes 
of chest pain. Differences in survival were assessed us-
ing the log-rank test. 
Figure 3. Kaplan-Meier curves for the cumulative sur-
vival according to the QTc interval. Kaplan-Meier curves 
displaying survival during 2 years of follow-up accord-
ing to the QTc interval in (A) the overall group of pa-
tients with chest pain, (B) the subgroup of patients with 
acute myocardial infarction, and (C) those with other 
causes of chest pain. Differences in survival were as-
sessed using the log-rank test. 
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assisting in the management of these patients are 
warranted. 
Diagnostic value of QRS duration  
and QTc interval
Current guidelines concerning the interpreta-
tion of 12-lead ECGs regarding the diagnosis of 
myocardial ischemia recommend focusing on ST-
-segment and T-wave alterations [1]. However, the 
diagnostic value of the 12-lead ECG particularly 
in patients without ST-elevations is limited [17].
In animal models, an association between 
myocardial ischemia and prolongation of QRS du-
ration has been shown [4–6]. Additionally clinical 
studies investigating QRS duration after induction 
of ischemia during coronary angiography showed 
direct proportionality between ischemia and QRS 
prolongation [6, 7, 27]. With regards to QT pro-
longation during myocardial ischemia, animal data 
as well as clinical data obtained during coronary 
angiography indicate that prolongation of the QT 
interval occurs much earlier and much more fre-
quent than ST-segment or T-wave changes in the 
course of myocardial ischemia [8]. Despite the es-
tablished association between myocardial ischemia 
and prolongation of both, the QRS duration as well 
Table 3. Uni- and multivariable Cox regression analysis for prediction of all cause all-cause mortality 
during long term follow up.
Univariate analysis Multivariable analysis
Hazard ratio P Hazard ratio P
Age — per year 1.10 (1.09–1.12) < 0.001 1.07 (1.06–1.09) < 0.001
Female sex 1.01 (0.79–1.30) 0.94
History of CAD 3.04 (2.39–3.86) < 0.001 1.24 (0.86–1.78) 0.25
History of MI 2.68 (2.12–3.38) < 0.001 1.35 (0.95–1.90) 0.10
Arterial hypertension 4.83 (3.34–6.98) <0.001 1.13 (0.76–1.67) 0.56
Diabetes 1.94 (1.50–2.52) < 0.001 1.16 (0.88–1.53) 0.28
COPD 2.57 (1.95–3.39) < 0.001 1.90 (1.43–2.54) < 0.001
Use of amiodarone 3.06 (1.75–5.34) < 0.001 1.48 (0.84–2.62) 0.18
Creatinine clearance* 0.96 (0.96–0.97) < 0.001 0.99 (0.99–1.00) 0.002
Hs-cTnT > 99 percentile 6.46 (4.92–8.49) < 0.001 1.54 (1.10–2.15) 0.01
Diagnosis of AMI 3.29 (2.61–4.12) < 0.001 1.33 (1.01–1.75) 0.04
Conventional ECG changes  
indicative of AMI
2.53 (2.00–3.21) < 0.001 1.51 (1.16–1.97) 0.002
Presence of LBBB 3.21 (2.22–4.63) < 0.001 1.09 (0.65–1.80) 0.75
Heart rate [bpm] 1.01 (1.01–1.01) < 0.001 1.01 (1.01–1.01) 0.01
QRS duration > 120 ms 2.95 (2.23–3.90) < 0.001 1.03 (0.70–1.52) 0.87
QTc interval > 440 ms 2.94 (2.32–3.71) < 0.001 1.40 (1.07–1.83) 0.01
*Per increase in mL/min/1.73 m2. Conventional electrocardiography (ECG) changes indicative of AMI include ST elevations, ST depressions 
and T-wave inversions. AMI — acute myocardial infarction; CAD — coronary artery disease; COPD — chronic obstructive pneumopathy;  
Hs-cTnT — high-sensitive cardiac troponin T; LBBB — left bundle branch block; MI — myocardial infarction 
suggestive of AMI. The following major findings 
are thus reported.
First, QRS duration and QTc interval were 
significantly longer in patients with AMI compared 
to patients with other causes of chest pain. How-
ever, due to a large overlap, the diagnostic value of 
both parameters was only modest and insufficient 
for added value in clinical practice (AUC 0.57 and 
0.60). Second, both a prolonged QRS duration and 
a prolonged QTc interval predicted an increased 
mortality during follow-up. This was observed 
both in the overall cohort as well as in important 
subgroups of patients with AMI and in patients with 
other causes of chest pain. Third, after multivari-
able adjustment, prolongation of the QTc interval 
remained an independent predictor of mortality, 
while a prolonged QRS duration was not. 
These findings have clinical implications: 
Patients presenting with acute chest pain are 
frequently seen in the ED and account for up to 
10% of all ED consultations [26]. Rapid diagnostic 
assessment and risk stratification in these patients 
is crucial medically, given that many have a re-
markably increased cardiovascular risk, but also 
economically given the large amount of patients 
[26]. Hence, additional easily available markers 
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as the QT interval, the diagnostic value of these 
two markers for the diagnosis of AMI, according 
to available research, has not been prospectively 
studied in unselected patients with chest pain. The 
present data indicates that despite a statistically 
significant prolongation of QRS duration and QTc 
interval in patients with AMI, the diagnostic value 
is limited and insufficient for use in clinical practice. 
The major reason for the limited diagnostic value 
is that there are many other reasons that affect for 
QRS duration and the QTc interval, particularly the 
occurrence of bundle branch blocks that dilute the 
potential effects induced by myocardial ischemia. 
Of importance, the assessment of intra-individual 
changes in QRS duration and QT interval compared 
to a prior ECG did not increase the diagnostic value 
in this study. 
Prognostic value of QRS duration  
and QTc interval
QRS prolongation and QT interval prolonga-
tion have been shown to predict mortality in pa-
tients who survived myocardial infarction [9–14]. 
Early studies have been carried out in the throm-
bolytic era [9–11]. Others that addressed the 
question in the era of PCI techniques were still 
dependent on the elevation of non-specific markers 
like creatinine kinase and liver enzymes regarding 
the diagnosis of AMI, and many patients enrolled 
were STEMI’s [12–14]. As a consequence, most 
of the AMI patients in those cohorts had large 
myocardial infarctions resulting in a substantial 
loss of myocardium. 
The present data corroborates previous stud-
ies in a way that prognostic value of a prolonged 
QRS duration and QTc interval can be extended 
to patients with smaller AMIs and NSTEMIs as 
diagnosed nowadays with high-sensitive cardiac 
troponin assays. Furthermore, a similar predictive 
value was found in patients presenting with acute 
chest pain overall, as well as in the subgroups of 
AMI patients, NSTEMI patients but also patients 
with chest pain other than AMI. One previous study 
has assessed prolongation of the QTc interval in 
NSTEMI patients and concluded that QTc is also 
a risk factor for mortality in these patients [28]. 
However, the findings in that study were based on 
a very low event rate of 4 deaths. 
Limitations of the study
Potential limitations of the present study merit 
consideration. First, the prognostic endpoint used 
in this study was all-cause mortality, but not sud-
den cardiac death. Classification of death in clinical 
practice can sometimes be difficult and unreliable 
[29]. In addition, despite the large number of pa-
tients, the event rate of sudden cardiac death would 
have been too limited to allow meaningful analysis. 
Second, serial ECG’s in these patients were not 
recorded and it cannot therefore  provide comment 
on the impact and significance of fluctuations in 
QRS duration and QTc interval in short time or 
during the first 24–48 h. Third, while information 
on cardiac medication including amiodarone was 
collected, no information was available on non-
cardiac medications potentially prolonging the 
QTc interval. 
Conclusions
QRS duration and QTc interval are signi-
ficantly prolonged in patients with AMI diagnosed 
based on hs-cTn levels compared to patients 
with other causes of chest pain. However, due 
to a large overlap, the diagnostic value of both 
parameters was insufficient for added value in 
clinical practice. With regards to prognosis, a pro-
longation of the QRS duration > 120 ms and of the 
QTc interval > 440 ms predicts mortality during 
follow-up. After adjustment for age and important 
ECG and clinical parameters, the QTc interval but 
not QRS duration remains an independent predic-
tor of mortality. 
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